SG11201808306PA - Treatment of cancer with tg02 - Google Patents
Treatment of cancer with tg02Info
- Publication number
- SG11201808306PA SG11201808306PA SG11201808306PA SG11201808306PA SG11201808306PA SG 11201808306P A SG11201808306P A SG 11201808306PA SG 11201808306P A SG11201808306P A SG 11201808306PA SG 11201808306P A SG11201808306P A SG 11201808306PA SG 11201808306P A SG11201808306P A SG 11201808306PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tgo2
- mab
- california
- pct
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 229940111134 coxibs Drugs 0.000 abstract 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 235000007328 Hericium erinaceus Nutrition 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662312712P | 2016-03-24 | 2016-03-24 | |
| US201662423468P | 2016-11-17 | 2016-11-17 | |
| PCT/US2017/023965 WO2017165732A1 (en) | 2016-03-24 | 2017-03-24 | Treatment of cancer with tg02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808306PA true SG11201808306PA (en) | 2018-10-30 |
Family
ID=59899752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202005621WA SG10202005621WA (en) | 2016-03-24 | 2017-03-24 | Treatment of cancer with tg02 |
| SG11201808306PA SG11201808306PA (en) | 2016-03-24 | 2017-03-24 | Treatment of cancer with tg02 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202005621WA SG10202005621WA (en) | 2016-03-24 | 2017-03-24 | Treatment of cancer with tg02 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11865116B2 (zh) |
| EP (1) | EP3432888B1 (zh) |
| JP (2) | JP7026299B2 (zh) |
| KR (2) | KR102491013B1 (zh) |
| CN (2) | CN115969854A (zh) |
| AU (1) | AU2017238647B2 (zh) |
| CA (1) | CA3018875A1 (zh) |
| ES (1) | ES2941687T3 (zh) |
| IL (1) | IL261959B2 (zh) |
| MX (2) | MX2021012977A (zh) |
| RU (1) | RU2749025C2 (zh) |
| SG (2) | SG10202005621WA (zh) |
| WO (1) | WO2017165732A1 (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117586403A (zh) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| WO2019035985A1 (en) | 2017-08-18 | 2019-02-21 | Tragara Pharmaceuticals, Inc. | POLYMORPHIC FORM OF TG02 |
| MX2021011301A (es) * | 2019-03-18 | 2022-01-19 | Univ Texas | Terapia combinada especifica contra tumores. |
| WO2020219603A1 (en) * | 2019-04-22 | 2020-10-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Use of tg02 for treating gliomas in pediatric subjects |
| WO2022035723A1 (en) * | 2020-08-10 | 2022-02-17 | The Broad Institute, Inc. | Compositions, panels, and methods for characterizing chronic lymphocytic leukemia |
| WO2023092076A1 (en) * | 2021-11-18 | 2023-05-25 | Lantern Pharma Inc. | Method for treating cancer with acylfulvene and radiation |
| CN114113051B (zh) * | 2021-12-16 | 2023-06-16 | 南京信息工程大学 | 一种psma电致化学发光传感器的制备方法及应用 |
| EP4197525A1 (en) | 2021-12-20 | 2023-06-21 | Scandion Oncology A/S | Combination of drugs for the treatment of cancer |
| CN114480639B (zh) * | 2021-12-24 | 2022-09-30 | 中国医学科学院北京协和医院 | 新靶点用于诊断和治疗垂体腺瘤 |
| CN116510024A (zh) * | 2022-01-30 | 2023-08-01 | 上海复东生物医药有限责任公司 | 一种组合物、其制备方法及应用 |
| WO2023242235A1 (en) | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
| CN115429793A (zh) * | 2022-08-15 | 2022-12-06 | 复旦大学附属中山医院 | 一种化合物在制备治疗肝细胞癌药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982001011A1 (en) | 1980-09-24 | 1982-04-01 | Corp Cetus | Diagnostic method and probe |
| ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| US8143255B2 (en) * | 2005-11-16 | 2012-03-27 | S*Bio Pte Ltd. | Heteroalkyl linked pyrimidine derivatives |
| UA115523C2 (uk) | 2010-02-05 | 2017-11-27 | Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" | Тверді форми макроциклічних інгібіторів кінази |
| CA2915622C (en) | 2013-06-21 | 2020-08-18 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| CA2920113A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| WO2015095840A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of cdk and erk inhibitors |
| WO2015153870A1 (en) * | 2014-04-04 | 2015-10-08 | Memorial Sloan-Kettering Cancer Center | Method and kits for identifying of cdk9 inhibitors for the treatment of cancer |
| US10233170B2 (en) * | 2014-04-08 | 2019-03-19 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| WO2019035985A1 (en) | 2017-08-18 | 2019-02-21 | Tragara Pharmaceuticals, Inc. | POLYMORPHIC FORM OF TG02 |
-
2017
- 2017-03-24 KR KR1020187030053A patent/KR102491013B1/ko active IP Right Grant
- 2017-03-24 JP JP2019500752A patent/JP7026299B2/ja active Active
- 2017-03-24 US US16/087,966 patent/US11865116B2/en active Active
- 2017-03-24 WO PCT/US2017/023965 patent/WO2017165732A1/en active Application Filing
- 2017-03-24 CA CA3018875A patent/CA3018875A1/en active Pending
- 2017-03-24 MX MX2021012977A patent/MX2021012977A/es unknown
- 2017-03-24 AU AU2017238647A patent/AU2017238647B2/en active Active
- 2017-03-24 CN CN202211276427.5A patent/CN115969854A/zh active Pending
- 2017-03-24 ES ES17771215T patent/ES2941687T3/es active Active
- 2017-03-24 EP EP17771215.5A patent/EP3432888B1/en active Active
- 2017-03-24 SG SG10202005621WA patent/SG10202005621WA/en unknown
- 2017-03-24 RU RU2018137217A patent/RU2749025C2/ru active
- 2017-03-24 CN CN201780032318.XA patent/CN109195603B/zh active Active
- 2017-03-24 KR KR1020237001967A patent/KR20230020549A/ko not_active Application Discontinuation
- 2017-03-24 SG SG11201808306PA patent/SG11201808306PA/en unknown
-
2018
- 2018-09-24 MX MX2022008868A patent/MX2022008868A/es unknown
- 2018-09-26 IL IL261959A patent/IL261959B2/en unknown
-
2022
- 2022-01-17 JP JP2022004776A patent/JP7459149B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3432888B1 (en) | 2022-10-05 |
| RU2018137217A (ru) | 2020-04-24 |
| JP7459149B2 (ja) | 2024-04-01 |
| WO2017165732A1 (en) | 2017-09-28 |
| MX2021012977A (es) | 2022-10-03 |
| CN109195603A (zh) | 2019-01-11 |
| AU2017238647A1 (en) | 2018-10-25 |
| IL261959B1 (en) | 2023-04-01 |
| IL261959A (en) | 2018-10-31 |
| CA3018875A1 (en) | 2017-09-28 |
| RU2749025C2 (ru) | 2021-06-03 |
| US20200323862A1 (en) | 2020-10-15 |
| US11865116B2 (en) | 2024-01-09 |
| JP7026299B2 (ja) | 2022-02-28 |
| CN115969854A (zh) | 2023-04-18 |
| JP2019509354A (ja) | 2019-04-04 |
| IL261959B2 (en) | 2023-08-01 |
| KR20190006948A (ko) | 2019-01-21 |
| JP2022050631A (ja) | 2022-03-30 |
| RU2018137217A3 (zh) | 2020-05-29 |
| KR20230020549A (ko) | 2023-02-10 |
| EP3432888A1 (en) | 2019-01-30 |
| MX2022008868A (es) | 2022-08-11 |
| AU2017238647B2 (en) | 2021-12-09 |
| CN109195603B (zh) | 2022-11-08 |
| EP3432888A4 (en) | 2019-11-13 |
| KR102491013B1 (ko) | 2023-01-31 |
| SG10202005621WA (en) | 2020-07-29 |
| ES2941687T3 (es) | 2023-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201901364VA (en) | Engineered target specific nucleases | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901959YA (en) | Modified stem cell memory t cells, methods of making and methods of using same | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof |